Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors.

Wanigasooriya, Kasun; Tyler, Robert; Barros-Silva, Joao D; Sinha, Yashashwi; Ismail, Tariq; Beggs, Andrew D

Wanigasooriya, Kasun; Tyler, Robert; Barros-Silva, Joao D; Sinha, Yashashwi; Ismail, Tariq; Beggs, Andrew D.

Afiliación

Wanigasooriya K; College of Medical and Dental Sciences, Institute of Cancer and Genomic Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Tyler R; The New Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK.
Barros-Silva JD; The New Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK.
Sinha Y; College of Medical and Dental Sciences, Institute of Cancer and Genomic Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Ismail T; College of Medical and Dental Sciences, Institute of Cancer and Genomic Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Beggs AD; The New Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK.

Cancers (Basel) ; 12(5)2020 May 18.

Article en En | MEDLINE | ID: mdl-32443649

Palabras clave

AKT; PI3K; chemoradiotherapy; glioblastoma multiforme; head and neck cancer; mTOR inhibitors; non-small cell lung cancer; prostate cancer; radiosensitiser; rectal cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google